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Pancreatic cancer shows a characteristic tissue structure called desmoplasia, which
consists of dense fibrotic stroma surrounding cancer cells. Interactions between
pancreatic cancer cells and stromal cells promote invasive growth of cancer cells and
establish a specific microenvironment such as hypoxia which further aggravates the
malignant behavior of cancer cells. Pancreatic stellate cells (PSCs) play a pivotal role
in the development of fibrosis within the pancreatic cancer tissue, and also affect
cancer cell function. PSCs induce epithelial-mesenchymal transition and cancer stem
cell (CSC)-related phenotypes in pancreatic cancer cells by activating multiple signaling
pathways. In addition, pancreatic cancer cells and PSCs recruit myeloid-derived suppressor
cells which attenuate the immune reaction against pancreatic cancer cells. As a result,
pancreatic cancer cells become refractory against conventional therapies. The formation
of the CSC-niche by stromal cells facilitates postoperative recurrence, re-growth of
therapy-resistant tumors and distant metastasis. Conventional therapies targeting cancer
cells alone have failed to conquer pancreatic cancer, but targeting the stromal cells and
immune cells in animal experiments has provided evidence of improved therapeutic
responses. A combination of novel strategies altering stromal cell functions could
contribute to improving the pancreatic cancer prognosis.
Keywords: desmoplasia, pancreatic stellate cells, bone marrow derived cells, epithelial-mesenchymal transition,
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INTRODUCTION
The prognosis of pancreatic cancer remains poor despite diag-
nostic and therapeutic improvements. A sensitive early detection
screening method has not yet become available, and clinical
symptoms such as obstructive jaundice or back pain are signs
of advanced disease. Most patients are not eligible for cura-
tive surgery, due to the local invasion and distant metastasis
(Hidalgo, 2010). Chemotherapy is an alternative treatment for
patients with unresectable disease, but complete remission of
pancreatic cancer by current regimens is rare. Postoperative
recurrence is also frequent, presenting as liver metastasis or peri-
tonitis carcinomatosa with a dismal prognosis (Hidalgo, 2010).
In the United States, there were an estimated 45,220 new cases
of pancreatic cancer in 2013 and more than 80% of those
patients are expected to die from the disease, suggesting a criti-
cal state (Siegel et al., 2013). According to the Japan Pancreatic
Cancer Registry, 3-year survival rate of pancreatic cancer was
approximately 20% (Egawa et al., 2012). These clinical out-
comes are attributed to the aggressive nature of pancreatic can-
cer cells, which reveal invasive growth into surrounding organs
and distant metastasis. Resistance against the conventional ther-
apy such as chemotherapy or radiation is also a formidable
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MAPK, mitogen-activated protein kinase; MDSCs, myeloid-derived suppressor
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problem in the clinical situation, but no radical solution has yet
appeared.
Previously, these biological behaviors of pancreatic cancer cells
were thought to result from cumulative gene mutations within
the cancer cell itself. Major mutations in pancreatic cancer have
been identified, such as an activating mutation of Kras, inac-
tivating mutations of tumor suppressor p16, p53, and Smad4
(Hong et al., 2011). These mutations accumulate along with
the increasing atypia of cells in the preneoplastic lesion, PanIN.
However, the contribution of stromal cells during the pancreatic
cancer progression is now widely recognized as playing crucial
roles in pancreatic cancer cell survival, invasion, and metasta-
sis. Pancreatic cancer shows a characteristic tissue structure called
desmoplasia, which consists of dense fibrotic stroma surround-
ing the cancer cells (Erkan et al., 2012b). Recent research has
revealed the involvement of a wide variety of host-derived normal
cells in the development of the pancreatic cancer-specific tissue
structure. Perpetuated inflammation caused by the unregulated
growth of pancreatic cancer cells leads to the formation of desmo-
plasia, which could act as a physical barrier for the pancreatic
cancer cells against the anti-cancer drugs and immune surveil-
lance (Evans and Costello, 2012; Kozono et al., 2013; Tang et al.,
2013). The activation of stromal cells by pancreatic cancer cells is a
persisting event and involves multiple signaling pathways such as
mitogen-activated protein kinase (MAPK) (Erkan et al., 2012a).
Pancreatic stellate cells (PSCs) reside within pancreatic
parenchyma and remain in a quiescent state in normal pancreas.
Quiescent PSCs contain vitamin A droplets in the cytoplasm
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(Masamune and Shimosegawa, 2009). Once activated by inflam-
mation, PSCs start to proliferate and undergo myofibroblast-like
phenotypic changes. Activated PSCs play a central role in pan-
creatic fibrosis by producing extracellular matrix (ECM) proteins
and cytokines (Masamune and Shimosegawa, 2009, 2013). In
addition to the residual PSCs, bone marrow-derived cells could
also contribute to the population of PSCs (Masamune et al.,
2009; Watanabe et al., 2009; Scarlett, 2013). After the bone mar-
row transplantation, bone marrow-derived cells accounted for
8.7% of PSCs in the pancreas. Induction of pancreatic fibrosis
increased the bone marrow-derived cells up to 20% of activated
PSCs (Watanabe et al., 2009). These bone marrow-derived cells
were also capable of contributing to the desmoplastic stroma
in a dimethylbenzanthracene-induced mouse pancreatic can-
cer model (Scarlett et al., 2011). These results suggest that
the transdifferentiation of extrapancreatic cells leads to their
involvement with pancreatic cancer cells as a stromal com-
ponent. Furthermore, other types of cells could be recruited
to the pancreatic cancer tissue. For example, pancreatic can-
cer induces the mobilization of myeloid-derived suppressor cells
(MDSCs), which results in the recruitment of MDSCs within
the tumor, leading to the attenuation of CD8+ T-cell functions
(Porembka et al., 2012). Local immunosuppression hampers the
efficient elimination of cancer cells promoting disease progres-
sion. Other types of cells, such as mast cells, also accumulate
within pancreatic cancer tissue, and activate PSCs (Ma et al.,
2013).
Various lines of evidence suggest that the progression of
pancreatic cancer requires interaction with host cells including
stromal cells, inflammatory cells and immune cells. This tumor-
stromal interaction modifies multiple cell functions such as pro-
liferation, invasion, survival, immune tolerance, andmaintenance
of the CSC function. The above mentioned cellular components
andmicroenvironment of pancreatic cancer form a secure fortress
for cancer cells by reinforcing each other. Since the establish-
ment of pancreatic cancer requires more than 10 years, such
interactions with pancreatic cancer cells should be a systemic phe-
nomenon, not restricted to the diseased pancreas (Yachida et al.,
2010). This review article focuses on the pancreatic cancer cells’
functions affected by cell-to-cell interactions with various types
of cells.
TUMOR-STROMAL INTERACTION PROMOTES INVASIVE
GROWTH OF PANCREATIC CANCER CELLS
The tumor promoting role of pancreatic cancer stroma was
first identified using PSCs isolated from surgically resected pan-
creatic cancer specimens. Subcutaneous co-injection of PSCs
with human pancreatic cancer cell lines increased tumor growth
(Bachem et al., 2005). Conditioned medium obtained from
a culture of PSCs enhanced cell growth, invasion, migra-
tion and colony-formation of pancreatic cancer cells in vitro
(Hwang et al., 2008). Co-injection of PSCs with human pan-
creatic cancer cell line BxPC3 in an orthotopic implantation
model resulted in increased primary tumor size and metastatic
foci, indicating the tumor-promoting role of PSCs in vivo
(Hwang et al., 2008). Similar results were reported using another
human pancreatic cancer cell line, MiaPaCa-2, describing that
PSC-conditioned medium enhanced cell growth and migra-
tion, but inhibited apoptosis (Vonlaufen et al., 2008). Co-
injection of PSCs with cancer cells also increased the primary
tumor size, regional invasion and distant metastasis (Vonlaufen
et al., 2008). These results suggest that the interaction between
PSCs and pancreatic cancer cells might affect the intracellu-
lar signal of pancreatic cancer cells. In a previous study, PSC-
conditioned medium activated MAPK and Akt pathways in
pancreatic cancer cells, suggesting that PSCs are capable of
mediating growth and survival-enhancing signals to cancer cells
(Hwang et al., 2008).
Following these studies, the detailed mechanisms of inva-
sive growth promotion by PSCs were extensively studied. PSCs
expressing CD10 were able to promote the invasiveness of
pancreatic cancer cells compared with CD10− PSCs both in
vitro and in vivo (Ikenaga et al., 2010). CD10+ PSCs pro-
duced higher amounts of matrix metalloproteinase 3 (MMP3)
than CD10− PSCs, whose siRNA-based knockdown attenuated
the invasive capacity of the pancreatic cancer cells (Ikenaga
et al., 2010). This study described that specific subpopula-
tions of PSCs have distinct roles during the progression of
pancreatic cancer. Another report described that PSCs resided
within the metastatic nodules derived from the orthotopic
implantation of pancreatic cancer cells with PSCs, suggesting
that PSCs accompany cancer cells to the metastatic site, sup-
porting colonization (Xu et al., 2010). This study confirmed
the transendothelial migration of cancer cell-stimulated PSCs,
which proved the capability of PSCs to extravasate to blood
vessels (Xu et al., 2010). These cell functions of PSCs con-
tribute to the establishment of an appropriate microenviron-
ment for cancer cells to survive in the invaded or metastasized
tissues.
The establishment of distant metastasis involves multiple pro-
cesses, including epithelial-mesenchymal transition (EMT). EMT
is characterized by the loss of epithelial phenotypes and gain
of mesenchymal phenotypes, increased cellular migration and
invasion, which is an indispensable process for the initiation
of metastasis (Polyak and Weinberg, 2009). PSCs were found
to trigger EMT in pancreatic cancer cells. Indirect co-culture
of pancreatic cancer cells with PSCs induced EMT compat-
ible phenotypic changes such as a fibroblast-like appearance
and loose cell-to-cell contact in human pancreatic cancer cell
lines Panc-1 and SUIT-2 (Kikuta et al., 2010). The expression
of E-cadherin, cytokeratin 19, and membrane-associated beta-
catenin was decreased, while the expression of Vimentin and
EMT-regulator Snail was increased. Along with the increased cel-
lular migration, these phenotypic changes were considered to be
compatible with EMT (Kikuta et al., 2010). In this study, block-
ade of a typical EMT-inducer, the transforming growth factor-β
(TGF-β) signal by anti-TGF-β-neutralizing antibody failed to
attenuate EMT induction, excluding a central role of TGF-β in
this process. Therefore, the mediators of these tumor-promoting
roles of PSCs remain elusive. The effect of direct cell-to-cell
contact between cancer cells and stromal cells or mechanical
stress from the tissue structure should be taken into account.
Further study needs to be carried out to clarify the tumor-stromal
interaction.
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CANCER STEM CELL-RELATED PHENOTYPES ARE AFFECTED
BY TUMOR-STROMAL INTERACTION
Normal organs maintain tissue stem cells, which give rise to
the various kinds of differentiated cells, to maintain the tissue
structure. Cancer stem cells (CSCs) are the counterpart of the
normal stem cells (Brabletz et al., 2009). In contrast to the nor-
mal stem cells, CSCs give rise to a wide variety of cancer cells
with various degrees of differentiation and can reconstruct an
entire population. CSCs also have self-renewal capacity, enabling
them to survive after conventional therapy and leading to post-
operative recurrence or re-growth of therapy-resistant tumors.
Furthermore, EMT and increased cellular migration/invasion
are some of the CSC-related phenotypes (Wellner et al., 2009).
Together with the ability to reconstruct the entire cancer cell
population, these phenotypes characterize: “migrating CSCs,”
which could initiate distant metastasis (Wellner et al., 2009).
Until now, CSCs-containing cell fractions of pancreatic can-
cer cells were isolated using several cell surface markers such
as CD44+CD24+ESA+ cells or CD133+ cells (Hermann et al.,
2007; Li et al., 2007). Though these cells are not identical with
pure CSCs, they reveal resistance to chemotherapeutic agents,
invasiveness, and self-renewal capacity. Theoretically, inhibition
of CSCs’ self-renewal could lead to curing pancreatic cancer.
However, extracellular factors, which define the stemness of CSCs
in pancreatic cancer, remain unclear. Since PSCs promote EMT
in pancreatic cancer cells, the possible contribution of PSCs in
the maintenance of stemness was assumed.
A recent report described that PSCs can enhance CSC-like
phenotypes in pancreatic cancer cells in vitro, inducing the
expression of the CSC-related genes ABCG2, Nestin, and LIN28
and increasing the spheroid formation in low-adhesion coated
plates, also a feature of CSCs (Hamada et al., 2012). Co-injection
of PSCs with pancreatic cancer cells also accelerated the subcuta-
neous tumor growth, suggesting the promotion of tumorigenicity
in vivo (Hamada et al., 2012). Another study identified that PSCs
form a niche for CSCs and promote self-renewal (Lonardo et al.,
2012). In this study, Nodal-expressing pancreatic stellate cells
could be an important component of the tumor stroma that
supports pancreatic CSCs. These findings suggest the possibility
of CSC-targeting strategies by inhibiting the cellular functions
of PSCs. Conventional chemotherapy could expand the can-
cer cell population with the CSC phenotype, which leads to
therapy-resistant tumors (Wang et al., 2009). The addition of
PSC-inhibiting agents to conventional chemotherapy might be
effective in reducing the therapy-resistant cancer cells.
DESMOPLASIA PROVIDES HYPOXIC MICROENVIRONMENT
Desmoplasia inhibits the perfusion of various molecules from
blood by separating cancer cells from the blood vessels. Such
a tissue structure also hampers oxygen perfusion, resulting in
severe hypoxia within the tumor. The expression level of hypoxia-
inducible factor 1 alpha (HIF1α) was correlated with the presence
of a fibrotic focus in pancreatic cancer tissue, suggesting desmo-
plasia provides a hypoxic condition within the tumor (Couvelard
et al., 2005). Exposure to a hypoxic condition stabilizes the tran-
scriptional factor HIF1α against proteasomal degradation, which
induces HIF1α-target genes such as vascular endothelial growth
factor (VEGF) or MMP3 (Duffy et al., 2003; Lin et al., 2008). In
addition, hypoxia could induce profibrogenic and proangiogenic
responses in PSCs, characterized by type I collagen expression and
VEGF production (Masamune et al., 2008). These results indi-
cate that the hypoxic condition derived from pancreatic fibrosis
could be amplified by the feed-forward loop, nourishing further
the hypoxic condition.
The hypoxic condition itself can exacerbate themalignant phe-
notype of pancreatic cancer cells. A previous report described that
tumor hypoxia correlated with the metastasis of cancer cells in
an orthotopic implantation model of pancreatic cancer (Buchler
et al., 2004). The downstream target genes induced by hypoxia,
VEGF and interleukin (IL)-6 enhance the invasive growth of
pancreatic cancer cells (Bao et al., 2012). In addition to these
conventional molecules, a novel class of molecules was recently
identified. miRNA is a small, non-coding RNA that interacts with
hundreds of target mRNAs, enabling the comprehensive regu-
lation of cellular functions (Farazi et al., 2011). Among these
miRNAs, miR-210 is specifically induced by hypoxia, and ele-
vated expression of miR-210 is associated with poor survival in
pancreatic cancer patients (Greither et al., 2010). Interestingly,
PSCs are able to induce miR-210 expression in pancreatic can-
cer cells even under normoxic conditions via the extracellular
signal-regulated kinase (ERK) and Akt pathways (Takikawa et al.,
2013). This HIF1α-independent miR-210 induction affected the
EMT of pancreatic cancer cells, suggesting an intriguing effect of
tumor-stromal interaction.
Hypoxia also contributes to the CSC-related phenotypes of
pancreatic cancer cells. Hypoxia induced the expression of the
putative pancreatic cancer stem cell marker CD133 in human
pancreatic cancer cell lines (Hashimoto et al., 2011). Besides
CD133, the expression of CXC chemokine receptor 4 was also
increased by hypoxia, and its expression was found in a highly-
invasive subpopulation of CSCs in another study (Hermann et al.,
2007). In addition, the expression of other stem-cell markers,
Nanog and Oct4, was increased by hypoxia in pancreatic can-
cer cells (Bao et al., 2012). Another study identified that HIF1α
inhibitor PX-478 sensitized pancreatic cancer cells to radiation
(Schwartz et al., 2009). Since resistance to radiation is one of
the CSC-related phenotypes, HIF1α-regulated signals might be
involved in the maintenance of stemness. Together with the
tumor-stromal interaction, hypoxia is thought to form a niche
for CSCs.
INTERACTION BETWEEN IMMUNE CELLS AND PANCREATIC
CANCER CELLS
Pancreatic cancer affects the host immune system to evade detec-
tion by immune surveillance. Examination of a mouse model
of pancreatic cancer revealed leukocytic infiltration around the
pre-invasive lesion of pancreatic cancer, consisting of MDSCs,
immunosuppressive cells recruited from bone marrow (Clark
et al., 2007). MDSCs are myeloid cells comprised of precursors of
macrophages, dendritic cells, and granulocytes. The production
of arginase, nitric oxide, and reactive oxygen species fromMDSCs
contributes to the suppression of T-cell functions (Ostrand-
Rosenberg and Sinha, 2009). These immune cells’ interactions
result in antigen-specific T-cell tolerance, a major mechanism
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of cancer cell escape from the host immune system (Wang,
2006). Detailed mechanisms by which pancreatic cancer affects
the differentiation of myeloid cells remain controversial, but sev-
eral markers of MDSCs [monocytic MDSC (CD11b+CD14+)
or granulocytic MDSC (CD11b+CD15+)] have been reported
(Goedegebuure et al., 2011).
The degree of MDSCs’ induction has an impact on pancreatic
cancer progression, and therefore affects the clinical outcomes.
For example, the amount of the peripheral blood MDSCs could
correlate with a patient’s prognosis. MDSCs were significantly ele-
vated in blood samples from cancer-bearing patients including
pancreatic cancer, and the MDSC level was found to be an inde-
pendent prognostic factor for patient survival (Gabitass et al.,
2011). This report also described the elevation of Th2 cytokine
IL-13 in a blood sample, which correlated with the MDSC level.
Another report described that MDSCs are related to chronic
inflammation in cancer-bearing patients, leading to the deteriora-
tion of the nutritional status (Ohki et al., 2012). The MDSC level
was inversely correlated with the serum concentration of total
protein, suggesting a systemic effect of tumor-induced MDSCs.
These observations suggest that the general condition of pancre-
atic cancer-bearing patients is modulated by the altered immune
reaction, which results from the interaction between pancreatic
cancer cells and immune cells.
PSCs’ CONTRIBUTION TO THE ALTERATION OF IMMUNE
CELL FUNCTIONS
In addition to pancreatic cancer cells, PSCs also modify the
immune cell functions. Pancreatic cancer-associated PSCs were
found to promote the differentiation of myeloid-derived cells to
MDSCs through the STAT3 pathway (Mace et al., 2013). The
induction of MDSCs from peripheral blood mononuclear cells
by PSC-conditioned medium was mediated by IL-6. MDSCs
induced by PSC-conditioned medium showed CD11b expression
and inhibited autologous T-cell proliferation. Targeting this sig-
naling pathway abrogated the PSC-conditioned medium-induced
MDSC differentiation, suggesting the possibility of a novel ther-
apy by inhibiting the induction of MDSCs. Indeed, suppressing
the functions of MDSCs by synthetic triterpenoid successfully
attenuated the tumor growth in mice through the restoration
of the immune reaction against cancer cells (Nagaraj et al.,
2010). These lines of evidence suggest that the differentiation and
recruitment of MDSCs into pancreatic cancer could be promising
therapeutic targets.
Furthermore, a recent report described that activated PSCs
sequester CD8+ T-cells and reduce infiltration around the tumor,
resulting in a reduced anti-tumor immune response (Ene-Obong
et al., 2013). The degree of CD8+ T-cell infiltration around
the tumor positively correlated with patients’ survival, indicat-
ing the contribution of the host immune reaction to inhibit-
ing the progression of pancreatic cancer (Ene-Obong et al.,
2013). A similar sequestration of CD8+ T-cells was observed
in a genetically-engineered mouse model of pancreatic cancer,
KPC mice (Ene-Obong et al., 2013). This mouse model devel-
ops invasive pancreatic cancer based on the conditional expres-
sion of mutant K-ras (constitutively active mutation G12D) and
mutant p53 (inactivating mutation R172H) in the pancreas,
recapitulating human pancreatic cancer including prominent
desmoplasia (Hingorani et al., 2005). All-trans retinoic acid
(ATRA) administration to KPC mice attenuated PSC activation
in KPC mice, which resulted in the restoration of CD8+ T-
cell infiltration around the pancreatic cancer cells. Interestingly,
PSCs-derived CXCL12 increased the chemotaxis of CD8+ T-cells
toward PSCs, the knockdown of which showed an identical effect
with ATRA (Ene-Obong et al., 2013). Inhibition of CXCL12 and
ATRA might become a novel therapeutic option to restore the
immune response against pancreatic cancer.
PSCs interact with another type of immune cells, which also
promote the growth of pancreatic cancer. Mast cells trigger type
I hypersensitivity in various diseases such as bronchial asthma
and urticaria (Beunk et al., 2013). The accumulation of mast cells
within pancreatic cancer was found in the pancreatic tumor of
a mouse model that conditionally expresses constitutively active
K-ras (G12V) in pancreas (Chang et al., 2011). This study con-
firmed the important role of mast cells in the pancreatic cancer
progression using an orthotopic implantation model. Pancreatic
tumor growth in mast cell-deficient Kit (w-sh/w-sh) mice that
received orthotopic implantation of pancreatic cancer cells was
suppressed, and the reconstitution of mast cells from wild-type
bone marrow aggravated the orthotopic tumor growth (Chang
et al., 2011). These results revealed a novel role of mast cells
as promoters of pancreatic cancer. Detailed mechanisms of the
role of mast cells in promoting cancer were examined there-
after. Pancreatic cancer cell-conditioned medium promoted mast
cell migration and co-culture of mast cells with pancreatic can-
cer cells or PSCs stimulated mast cell activation, confirmed by
the release of tryptase and tumor necrosis factor-α (Ma et al.,
2013). Mast cells promoted the proliferation of PSCs and mast
cell-derived IL-13 mediated this process. Interestingly, the IL-13
elevation was also correlated with the increase ofMDSCs, suggest-
ing possible cross-talk. Recent research noted that mast cells can
enhance the immunosuppressive functions of MDSCs, support-
ing this speculation (Saleem et al., 2012). Taken together, mast
cells contribute to pancreatic cancer progression by increasing cell
proliferation and activating PSCs. Targeting mast cells for pancre-
atic cancer treatment has not yet been evaluated, but this strategy
might yield an additional way to suppress the stromal reaction
and immunosuppression in pancreatic cancer.
TARGETING TUMOR-STROMAL INTERACTION; POSSIBILITY
AND PROBLEMS
As summarized in this review, tumor-stromal interaction has piv-
otal role in pancreatic cancer progression. Interventions directed
to the desmoplasia-inducing signaling pathways revealed favor-
able effects, such as the inhibition of Shh pathway or CTGF
pathway in mouse model (Olive et al., 2009; Neesse et al., 2013).
However, the phase II clinical trial of Shh inhibitor IPI-926
halted due to the significantly shorter survival in patients on
the gemcitabine plus IPI-926 arm. This result might be due to
the heterogeneity of human disease, distinct from the relatively
homogeneous nature of tumors in the mouse model, arising from
uniform genetic background. It is also possible that simple deple-
tion of fibrotic stroma promotes cancer cell spread. To conquer
these discrepancies between human disease and mouse model,
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FIGURE 1 | Schematic view of tumor-stromal interactions affecting
invasive growth and escape from immune surveillance. Promotion of
invasive phenotype is mainly provided by activated PSCs. PSC activation
and MDSC induction are stimulated by cancer cells. MDSCs,
myeloid-derived suppressor cells; PSCs, pancreatic stellate cells; ROS,
reactive oxygen species.
detailed examination of clinical samples and further understand-
ing about the diversity of human disease are required.
Targeting immune cells could be an alternative approach to
modify the tumor microenvironment. Restoring the immune
reaction could be performed by several agents, such as ATRA
or IL-12 in mouse model, which exhibited therapeutic effects
(Kerkar et al., 2011; Ene-Obong et al., 2013). ATRA was also used
to induce differentiation of MDSCs in patients with metastatic
renal cell carcinoma, without significant toxicity (Mirza et al.,
2006). Use of these agents in combination with conventional
chemotherapy could have some benefits that needs to be evalu-
ated by further study.
CONCLUSION
Pancreatic cancer is a deadly disease and its establishment pro-
ceeds silently. Stromal reaction and escape from immune surveil-
lance are perpetuating systemic changes. The involvement of stro-
mal cell activation and immunosuppression enable cancer cells
to remain in a favorable niche, leading to distant metastasis and
therapy resistance. A schematic view of the cancer cell-stromal cell
interaction is shown in Figure 1. Conventional strategies that tar-
get the cancer cells themselves failed to cure pancreatic cancer,
due to the evolution in cancer cells and protection by the tumor
stroma. However, tumor stromal cells originally maintain normal
signaling pathways and relatively homogenous characteristics,
showing better therapeutic responses than pancreatic cancer cells.
Among these types of cells, PSCs show multifaceted roles in
modulating cell-to-cell interactions. PSCs’ contribution to the
multiple interactions is summarized in Figure 2. Targeting PSCs,
immune cells and the tumor stromal structure could be alterna-
tive therapies for pancreatic cancer. Further study is required to
improve the clinical outcomes of pancreatic cancer patients.
FIGURE 2 | Schematic view of PSCs’ multifaceted roles in modulating
cell-to-cell interactions. Activated PSCs, mast cells, and MDSCs foam
complex network that modify tumor microenvironment. CSCs, cancer stem
cells; EMT, epithelial-mesenchymal transition; MDSCs, myeloid-derived
suppressor cells; PSCs, pancreatic stellate cells; ROS, reactive oxygen
species.
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